281 related articles for article (PubMed ID: 17905438)
1. Tipranavir exhibits different effects on opportunistic pathogenic fungi.
Cenci E; Francisci D; Belfiori B; Pierucci S; Baldelli F; Bistoni F; Vecchiarelli A
J Infect; 2008 Jan; 56(1):58-64. PubMed ID: 17905438
[TBL] [Abstract][Full Text] [Related]
2. A synthetic peptide as a novel anticryptococcal agent.
Cenci E; Bistoni F; Mencacci A; Perito S; Magliani W; Conti S; Polonelli L; Vecchiarelli A
Cell Microbiol; 2004 Oct; 6(10):953-61. PubMed ID: 15339270
[TBL] [Abstract][Full Text] [Related]
3. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.
Rachini A; Pietrella D; Lupo P; Torosantucci A; Chiani P; Bromuro C; Proietti C; Bistoni F; Cassone A; Vecchiarelli A
Infect Immun; 2007 Nov; 75(11):5085-94. PubMed ID: 17606600
[TBL] [Abstract][Full Text] [Related]
4. The influence of antifungal antibiotics on some determinants of virulence in Candida albicans and Cryptococcus neoformans cells.
Borowski J; Jakoniuk P; Jablońska W; Jakubicz W; Szpak A
Experientia; 1974 Oct; 30(10):1210-1. PubMed ID: 4611784
[No Abstract] [Full Text] [Related]
5. New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans
Lu RY; Ni TJ; Wu J; Yan L; Lv QZ; Li LP; Zhang DZ; Jiang YY
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791946
[TBL] [Abstract][Full Text] [Related]
6. Antifungal activity of peptide MSI-1 against Cryptococcus neoformans infection in vitro and in murine cryptococcal meningoencephalitis.
Ma L; Wei S; Ye X; Xu P; Chen H; Liu Z; Zhou C
Peptides; 2020 Aug; 130():170334. PubMed ID: 32504765
[TBL] [Abstract][Full Text] [Related]
7. Indinavir-treated Cryptococcus neoformans promotes an efficient antifungal immune response in immunosuppressed hosts.
Pericolini E; Cenci E; Monari C; Perito S; Mosci P; Bistoni G; Vecchiarelli A
Med Mycol; 2006 Mar; 44(2):119-26. PubMed ID: 16519014
[TBL] [Abstract][Full Text] [Related]
8. Phospholipase activity in Cryptococcus neoformans.
Vidotto V; Sinicco A; Di Fraia D; Cardaropoli S; Aoki S; Ito-Kuwa S
Mycopathologia; 1996-1997; 136(3):119-23. PubMed ID: 9276940
[TBL] [Abstract][Full Text] [Related]
9. Glyphosate inhibits melanization of Cryptococcus neoformans and prolongs survival of mice after systemic infection.
Nosanchuk JD; Ovalle R; Casadevall A
J Infect Dis; 2001 Apr; 183(7):1093-9. PubMed ID: 11237835
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in cryptococcosis, candidiasis and coccidioidomycosis complicating HIV infection.
Kappe R; Levitz S; Harrison TS; Ruhnke M; Ampel NM; Just-Nübling G
Med Mycol; 1998; 36 Suppl 1():207-15. PubMed ID: 9988509
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulator tuftsin increases the susceptibility of Cryptococcus neoformans to liposomal amphotericin B in immunocompetent BALB/c mice.
Khan MA; Owais M
J Drug Target; 2005 Aug; 13(7):423-9. PubMed ID: 16308211
[TBL] [Abstract][Full Text] [Related]
12. Experimental systemic infection with Cryptococcus neoformans var. grubii and Cryptococcus gattii in normal and immunodeficient mice.
Capilla J; Maffei CM; Clemons KV; Sobel RA; Stevens DA
Med Mycol; 2006 Nov; 44(7):601-10. PubMed ID: 17071553
[TBL] [Abstract][Full Text] [Related]
13. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.
Mehandru S; Markowitz M
Expert Opin Investig Drugs; 2003 Nov; 12(11):1821-8. PubMed ID: 14585057
[TBL] [Abstract][Full Text] [Related]
14. Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans.
Sanguinetti M; Posteraro B; La Sorda M; Torelli R; Fiori B; Santangelo R; Delogu G; Fadda G
Infect Immun; 2006 Feb; 74(2):1352-9. PubMed ID: 16428784
[TBL] [Abstract][Full Text] [Related]
15. Isolation and characterization of senescent Cryptococcus neoformans and implications for phenotypic switching and pathogenesis in chronic cryptococcosis.
Jain N; Cook E; Xess I; Hasan F; Fries D; Fries BC
Eukaryot Cell; 2009 Jun; 8(6):858-66. PubMed ID: 19411622
[TBL] [Abstract][Full Text] [Related]
16. Amino Acid Permeases and Virulence in Cryptococcus neoformans.
Martho KF; de Melo AT; Takahashi JP; Guerra JM; Santos DC; Purisco SU; Melhem MS; Fazioli RD; Phanord C; Sartorelli P; Vallim MA; Pascon RC
PLoS One; 2016; 11(10):e0163919. PubMed ID: 27695080
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
[TBL] [Abstract][Full Text] [Related]
18.
Chitty JL; Blake KL; Blundell RD; Koh YQAE; Thompson M; Robertson AAB; Butler MS; Cooper MA; Kappler U; Williams SJ; Kobe B; Fraser JA
J Biol Chem; 2017 Jul; 292(28):11829-11839. PubMed ID: 28559277
[TBL] [Abstract][Full Text] [Related]
19. Discrepancy between in vitro and in vivo antifungal activity of albendazole.
Hardin TC; Najvar LK; Rizzo J; Fothergill AW; Rinaldi MG; Graybill JR
J Med Vet Mycol; 1997; 35(3):153-8. PubMed ID: 9229330
[TBL] [Abstract][Full Text] [Related]
20. A case of fluconazole, voriconazole-resistant Cryptococcus neoformans isolated from and immunocompetent patient.
Mandras N; Roana J; Tullio V; Allizond V; Banche G; Scalas D; Fucale G; Cuffini AM
J Chemother; 2011 Dec; 23(6):379-80. PubMed ID: 22233828
[No Abstract] [Full Text] [Related]
[Next] [New Search]
